We are delighted to announce that Guillaume Canaud has been awarded the prestigious Prix Innovation 2024 by INSERM. This award recognizes his groundbreaking work in developing the first effective treatment for the rare and severe CLOVES syndrome, offering new hope to affected patients.

Pr. Canaud's innovative approach involves the use of alpelisib, a molecule initially developed for oncology, to inhibit the overactive PIK3CA protein responsible for the syndrome's manifestations. This therapeutic strategy has led to significant improvements in patients' health and quality of life.

Join us in congratulating Pr. Canaud and his team for this remarkable achievement, which exemplifies the impact of translational research in transforming patient care.